AU Patent

AU2018206695C1 — Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Assigned to Aragon Pharmaceuticals Inc · Expires 2020-10-22 · 6y expired

What this patent protects

Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.

USPTO Abstract

Described herein are methods of treating non-metastatic castrate-resistant prostate cancer with anti-androgens.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018206695C1
Jurisdiction
AU
Classification
—
Expires
2020-10-22
Drug substance claim
No
Drug product claim
No
Assignee
Aragon Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.